Similar quality in chronic kidney disease multidisciplinary follow-up between kidney transplant and non-transplant pre-dialysis patients

Qualidade semelhante no acompanhamento multidisciplinar de doença renal crônica entre pacientes pré-dialíticos transplantados e não transplantados

ABSTRACT

Introduction: Multidisciplinary clinics are the best approach towards Chronic Kidney Disease (CKD) patients in pre-dialysis phases. The few studies regarding kidney transplant recipients (KTR) compare multidisciplinary and non-multidisciplinary clinics. Methods: In this study, we compared the quality of multidisciplinary CKD care between 101 KTR and 101 propensity score-matched non-transplant pre-dialysis patients (PDP). Prevalence of patients without specific treatment at any time and percent time without specific treatment for CKD complications were the main outcomes and patient and kidney function survival, glomerular filtration rate (GFR) decline, prevalence of CKD-related complications, and percent time within therapeutic goals were the exploratory ones. Results: Time within most goals was similar between the groups, except for diastolic blood pressure (83.4 vs. 77.3%, RR 0.92, CI 0.88-0.97, p = 0.002) and hypertriglyceridemia (67.7 vs. 58.2%, OR 0.85, CI 0.78-0.93, p < 0.001), better in non-transplant PDP, and for proteinuria (92.7 vs. 83.5%, RR 1.1, CI 1.05-1.16, p < 0.001), better in KTR. Patient survival and GFR decline were similar between the groups, although non-transplant PDP tended to progress earlier to dialysis (9.9% vs. 6.9%, HR 0.39, p = 0.07, CI 0.14-1.08). Discussion: The similar findings between non-transplant PDP and KTR suggests that good and comparable quality of multidisciplinary is a valid strategy for promoting optimal clinical management of CKD-related complications in KTR.

Keywords: Renal Insufficiency, Chronic; Kidney Transplantation; Patient Care Team; Health Services Research; Graft Survival.

RESUMO

Introdução: Clínicas multidisciplinares são a melhor abordagem para pacientes com doença renal crônica (DRC) em fases pré-dialíticas. Os poucos estudos sobre receptores de transplante renal (RTR) comparam clínicas multidisciplinares e não multidisciplinares. Métodos: Neste estudo, comparamos a qualidade do atendimento multidisciplinar para DRC entre 101 RTR e 101 pacientes pré-dialíticos (PPD) não transplantados pareados com escore de propensão. A prevalência de pacientes sem tratamento específico em qualquer momento e a porcentagem de tempo sem tratamento específico para complicações de DRC foram nossos desfechos principais, e a sobrevida do paciente e da função renal, declínio da taxa de filtração glomerular (TFG), prevalência de complicações relacionadas à DRC e porcentagem de tempo dentro dos objetivos terapêuticos foram os exploratórios. Resultados: O tempo no alvo para a maioria dos objetivos foi semelhante entre os grupos, exceto para a pressão arterial diastólica (83.4 vs. 77.3%, RR 0.92, IC 0.88-0.97, p = 0.002) e hipertrigliceridemia (67.7 vs. 58.2%, OR 0.85, IC 0.78-0.93, p < 0.001), melhor em PPD não transplantados, e para proteinúria (92.7 vs. 83.5%, RR 1.1, IC 1.05-1.16, p < 0.001), melhor em RTR. A sobrevida do paciente e o declínio da TFG foram semelhantes entre os grupos, embora PPD não transplantados tendessem a progredir mais cedo para a diálise (9.9% vs. 6.9%, HR 0.39, p = 0.07, IC 0.14-1.08). Discussão: Os resultados semelhantes entre PPD não transplantados e os RTR sugerem que a qualidade multidisciplinar boa e comparável é uma estratégia válida para promover a gestão clínica ideal de complicações relacionadas à DRC em RTR.

Descritores: Insuficiência Renal, Crônica; Transplante Renal; Equipe de Assistência ao Paciente; Pesquisa de Serviços de Saúde; Sobrevivência de Enxerto.
CKD multidisciplinary care in transplant patients

**INTRODUCTION**

Kidney transplant is the best modality of renal replacement therapy (RRT) for patients with end-stage chronic kidney disease (CKD), providing lower mortality rate, better quality of life, and better control of CKD-related complications and comorbidities, such as hypertension, anemia, bone mineral disorder, metabolic acidosis, and hypervolemia.1,2

As stated in the Kidney Disease Improving Global Outcomes (KDIGO) guidelines, kidney transplant recipients (KTR) are a particular subset of patients with CKD. These patients, in addition to alloimmune phenomena and potentially life-threatening side effects from immunosuppressive drugs, may also undergo CKD progression and dialysis. During this process, KTR experience severe endothelial derangement, with enhanced risk of hard cardiovascular endpoints and progression to category 5 CKD, similar to non-transplant pre-dialysis patients (NT-PDP).3-5 Long-term patient and graft survival have modestly improved over recent decades.6,7 Alloimmune risks, including human leukocyte antigen (HLA) incompatibility, exposure to donor-specific antibodies, rejection episodes, and graft function at 1 year post-transplant are the major determinants of long-term kidney function survival. However, there is growing interest in classical clinical factors such as hypertension, proteinuria, anemia, diabetes, dyslipidemia, bone mineral disorders, and metabolic acidosis that contribute to CKD progression, notably after the first year post-transplant.8-10 Multidisciplinary clinics are the best model for clinical management of NT-PDP, but insufficient attention is directed at classical CKD-related complications in KTR, which are all classified as pre-dialysis patients (PDP).1 Few studies describe the impact of multidisciplinary approach on the treatment of CKD in KTR, mostly through comparisons between multidisciplinary and non-multidisciplinary clinics.1-14 The present study compares the quality of treatment of CKD-related complications between KTR and NT-PDP and explores the CKD progression when both cohorts are followed in multidisciplinary clinics.

**METHODS**

This retrospective study included patients followed at the Nephrology unit of the Federal University of Juiz de Fora, Brazil, between January 1, 2010 and December 31, 2014. At this CKD clinic, a multidisciplinary team of nephrologists, nurses, dietitians, social assistants, and psychologists routinely assist all NT-PDP and KTR. At each office visit, the whole multidisciplinary team evaluated all scheduled patients following a detailed care program, defined based on published guidelines, adapted after discussion with local facilities’ administrators.5,15 Visit intervals were individualized and planned to be no longer than three months. Inclusion criteria were: PDP in categories 1 to 5, age 18-70 years (upper limit to KT), follow-up > 1 year post-transplant for KTR, and > 1 year of clinic follow-up for NT-PDP. Exclusion criteria were lack of birthdate, weight, height, transplant date for KTR, or at least two measures of serum creatinine plus two systolic (SBP) and diastolic blood pressure (DBP) measurements in the first follow-up year. Of 876 NT-PDP and 158 KTR, 447 NT-PDP and 101 KTR matched inclusion criteria and were selected for the study. Furthermore, 101 of 447 NT-PDP were selected through a “nearest neighbor” propensity score-matching (PSM) model (considering age, sex, race, body mass index (BMI), obesity, CKD category, hypertension, diabetes, coronary artery disease, cerebrovascular disease, peripheral artery disease, and congestive heart failure), resulting in a study sample of 101 NT-PDP and 101 KTR (Figure 1).16

Demographic data included age, sex, race, etiology of CKD, comorbidities (hypertension, diabetes, obesity, cardiovascular disease, and smoking), and specific characteristics of KTR (dialysis duration, donor type, HLA matches, and immunosuppressive drugs). Estimated glomerular filtration rate (eGFR)
was calculated with the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) formula.\textsuperscript{17}

CKD-related complications were defined as: systolic hypertension (> 140 mmHg, or > 130 mmHg in diabetic patients with proteinuria > 300 mg/24h, or use of anti-hypertensives), diastolic hypertension (> 90 mmHg, or > 80 mmHg in diabetic patients with proteinuria > 300 mg/24h, or use of anti-hypertensives), clinically significant proteinuria (> 1 g/24h), anemia (hemoglobin <11 g/dL until December 31\textsuperscript{st}, 2013, or < 10 g/dL after January 1\textsuperscript{st}, 2014, or use of erythropoietin), hypocalcaemia (calcium < 8.5 mg/dL), hyperphosphatemia (phosphate > 4.5 mg/dL for patients in CKD categories 1-4, or > 5.5 mg/dL for patients in CKD category 5, or phosphate chelation), hyperparathyroidism (PTH > 450 pg/mL, or use of 1,25-OH-vitamin D), hypovitaminosis D (25-OH-vitamin D < 30 ng/mL, or use of 25-OH-vitamin D), hypercholesterolemia (total cholesterol > 200 mg/dL, or use of statins), low HDL ( < 50 mg/dL for women and < 55 mg/dL for men), hypertriglyceridemia (> 150 mg/dL), hyperuricemia (> 8.0 mg/dL, or use of allopurinol), and metabolic acidosis (bicarbonate <22 mEq/L, or use of sodium bicarbonate), according to the Brazilian and international guidelines for CKD management.\textsuperscript{5,15}

We compared the percentage of KTR and NT-PDP patients with CKD-related complications, both at baseline and throughout follow-up. Next, we assessed the percentage of follow-up visits wherein KTR and NT-PDP patients received specific treatments for those complications to measure treatment quality. We compared the percentage of follow-up visits wherein KTR and NT-PDP patients were within therapeutic goals to measure treatment performance.

Statistical analysis consisted of a comparative description of clinical and laboratory characteristics between the cohorts, by means (± standard deviation) or medians (and range), after analyzing sample normality using the Kolmogorov-Smirnov and Shapiro-Wilk tests, and determining categorical variable frequencies. As the main outcome for evaluating the CKD care quality between the two groups, we considered the percentage of follow-up visits wherein KTR and NT-PDP patients received specific treatments. In addition, as exploratory outcomes of treatment performance, we accounted for the percentage of follow-up visits wherein KTR and NT-PDP patients were within therapeutic goals and patient and dialysis-free kidney function survival. For each clinical complication and untreated complication, we assessed frequencies, odds ratios, relative risks, 95% confidence intervals (CI) and p values. Chi-square or t-tests were used for each subset of variables. Kaplan-Meier analysis was employed to assess patient and dialysis-free kidney function survival compared by log-rank testing. A mixed linear model permitted comparative analysis of GFR decay between the two cohorts. SPSS 20.0 (IBM, Chicago, Illinois, USA), Stata 13.0 (Stata Corporation, College Station, Texas, USA) and MedCalc (MedCalc Software, B-8400, Ostend, Belgium) were used for the analyses.

The study was approved by the local Ethics Committee (approval number 275/2011, December 15\textsuperscript{th}, 2011), and was conducted in accordance with ethical standards of the 1975 Helsinki Declaration and later amendments or comparable standards. Informed consent was waived by the local ethics committee.

**RESULTS**

The study included 101 NT-PDP and 101 KTR (Figure 1). After PSM selection of NT-PDP, baseline characteristics such as GFR, cardiovascular comorbidities, and CKD category distribution were matched. KTR were younger than NT-PDP (43.4±12.5 vs 50.2±13.5 years), with lower BMI (24.7±4.4 vs. 26.1±4.4), and longer follow-up (55.7±12.1 vs 31.6±11.5 months). Among NT-PDP, the predominant cause of CKD was hypertensive nephrosclerosis, whereas in KTR it was chronic glomerulonephritis (Table 1).

Most KTR had living related-donors (84.2%), and 3 HLA matches (54.5%). The median time spent on dialysis was 20 months (0-112 months), and 12 transplants were pre-emptive. Acute rejection was observed in 9.9%, and new-onset diabetes in 17.8%. Immunosuppression more often comprised prednisone (89.1%), mycophenolate (73.2%), and tacrolimus (56.4%). Most KTR were on triple therapy (89.1%), and 79.1% received calcineurin inhibitors (Table 2). Prescription of medications for CKD-related complications was similar between groups, except for erythropoietin, more common in KTR (28.7% vs. 3.96%, \textit{p} < 0.001), and cholecalciferol, more common in NT-PDP (48.5% vs. 2.97%, \textit{p} < 0.001) (Table 1).
### Table 1: Demographic and Clinical Characteristics of NT-PDP and KTR

|                        | NT-PDP (N = 101) | KTR (N = 101) | P    |
|------------------------|------------------|---------------|------|
| **Demographics**       |                  |               |      |
| Age (years)            | 50.2 ± 13.5      | 43.4 ± 12.5   | <0.001 |
| Female sex (%)         | 37.6             | 31.7          | 0.46  |
| Caucasian race (%)     | 54.4             | 74.2          | 0.003 |
| Body mass index (kg/m²)| 26.18            | 24.78         | 0.025 |
| Follow-up (months)     | 31.61            | 55.77         | <0.001 |
| **Renal function**     |                  |               |      |
| Creatinine (mg/dL)     | 1.62 ± 0.61      | 1.59 ± 0.53   | 0.735 |
| eGFR (mL/min/1.73m²)   | 51.69 ± 20.18    | 53.27 ± 16.88 | 0.548 |
| **CKD category at baseline (%)** |                |               | 0.509 |
| 1                      | 2.9              | 2.9           |      |
| 2                      | 24.8             | 29.7          |      |
| 3a                     | 40.6             | 36.6          |      |
| 3b                     | 22.8             | 24.8          |      |
| 4                      | 8.9              | 5.9           |      |
| 5                      | 0                | 0             |      |
| **Primary cause of CKD (%)** |              |               | 0.397 |
| Hypertensive           | 43.6             | 20.8          |      |
| Glomerulonephritis     | 12.9             | 40.6          |      |
| Diabetes               | 4.0              | 2.0           |      |
| Adult polycystic kidney disease | 11.9   | 5.0           |      |
| Other                  | 6.9              | 5.9           |      |
| Undetermined           | 20.8             | 25.7          |      |
| **Comorbidities at Baseline (%)** |              |               |      |
| Hypertension           | 92.1             | 86.1          | 0.175 |
| Diabetes               | 4.95             | 2.97          | 0.251 |
| Obesity                | 20.8             | 11.9          | 0.088 |
| Coronary artery disease| 6.93             | 6.93          | 1.0   |
| Peripheral artery disease| 2.97             | 0.99          | 0.315 |
| Cerebrovascular disease| 4.95             | 1.98          | 0.251 |
| Congestive heart failure| 5.94             | 3.96          | 0.519 |
| Smoking                | 9.9              | 8.9           | 0.808 |
| **Baseline clinical characteristics** |              |               |      |
| Systolic blood pressure (mmHg) | 1376 ± 25.3   | 125.1 ± 13.1  | <0.001 |
| Diastolic blood pressure (mmHg) | 85.5 ± 13.9     | 80.0 ± 11.0  | 0.002 |
| Haemoglobin (g/dL)     | 13.5 ± 1.5       | 12.7 ± 1.67   | <0.001 |
| Proteinuria (mg/24h)   | 169(10-5650)     | 184(15-1500)  | 0.071 |
| Total cholesterol (mg/dL) | 189.8 ± 43.4    | 186.6 ± 37.8  | 0.598 |
| LDL cholesterol (mg/dL) | 115.0 ± 35.8    | 109.7 ± 28.3  | 0.291 |
| HDL cholesterol (mg/dL) | 50.4 ± 14.7     | 46.4 ± 13.5   | 0.056 |
| Triglycerides (mg/dL)  | 138.1 ± 78.1     | 151.4 ± 96.8  | 0.33  |
| Calcium (mg/dL)        | 9.4 ± 0.7        | 9.7 ± 0.7     | 0.033 |
| Phosphorus (mg/dL)     | 3.6 ± 0.7        | 3.4 ± 0.8     | 0.124 |
| PTH (pg/mL)            | 63 (76-784)      | 76.7 (19-530) | 0.886 |
### Table 1. Continued.

|                  | NT-PDP (n = 10) | KTR (n = 10) | p-value |
|------------------|-----------------|--------------|---------|
| Cholecalciferol (ng/mL) | 23.5 (2-42)     | 24.4 (16.7-38) | 0.872   |
| Albumin (g/dL)    | 4.0 ± 0.5       | 4.2 ± 0.5    | 0.144   |
| Bicarbonate (mEq/L) | 24.6 ± 3.6     | 23.3 ± 2.6   | 0.113   |
| Uric Acid (mg/dL) | 6.6 ± 1.6       | 6.3 ± 1.5    | 0.246   |

**Overall use of key medications (%)**

| Medication                  | NT-PDP (n = 10) | KTR (n = 10) | p-value |
|-----------------------------|-----------------|--------------|---------|
| Anti-hypertensives          | 94.0            | 90.1         | 0.298   |
| ACEi or ARB                 | 87.1            | 78.2         | 0.127   |
| Betablockers                | 45.5            | 38.6         | 0.32    |
| ASA                         | 17.8            | 15.8         | 0.707   |
| Statins                     | 49.5            | 61.3         | 0.092   |
| Phosphate binder            | 5.94            | 4.95         | 0.757   |
| 1,25 OH Vitamin D           | 4.95            | 2.97         | 0.476   |
| Cholecalciferol             | 48.5            | 2.97         | < 0.001 |
| Erythropoietin              | 3.96            | 28.7         | < 0.001 |
| Bicarbonate                 | 14.8            | 19.8         | 0.355   |
| Allopurinol                 | 16.8            | 10.9         | 0.227   |

1Data are shown as percentages, means ± standard deviation, or medians. Continuous variables were compared using the t-test or Mann-Whitney U test, and frequencies were compared using the Chi-square test or Fisher test. 2 NT-PDP: non-transplanted pre-dialysis patients; KTR: kidney transplant recipients; eGFR: estimated glomerular filtration rate, according to the CKD-EPI formula; CKD: chronic kidney disease; ACEi: angiotensin-converting enzyme inhibitors; ARB: angiotensin receptor blocker; ASA: acetylsalicylic acid; LDL: low-density lipoprotein; HDL: high-density lipoprotein; PTH: parathyroid hormone.

### Table 2. Specific Clinical Characteristics of KTR

| Donor Type (%) |         |
|----------------|---------|
| Living related | 84.2    |
| Living unrelated | 11.9  |
| Deceased       | 3.9     |

| HLA matches (%) |         |
|-----------------|---------|
| 0-2             | 26.7    |
| 3               | 54.5    |
| 6               | 18.8    |

| Median time on dialysis (months) | 20 (0 – 112, 12 preemptive transplants) |
|----------------------------------|----------------------------------------|

| Complications during follow-up (%) |         |
|------------------------------------|---------|
| Delayed graft function             | 5.94    |
| Acute rejection                    | 9.9     |
| Post-transplant Diabetes           | 17.8    |

| Immunosuppression (%) |         |
|-----------------------|---------|
| Prednisone            | 89.1    |
| Tacrolimus            | 56.4    |
| Cyclosporine          | 23.7    |
| Mycophenolate         | 73.2    |
| Azathioprine          | 26.7    |
| Rapamycin             | 32.6    |
| Everolimus            | 8.9     |
| Triple medication      | 89.1    |
| Calcineurin inhibitor  | 79.1    |

1Data are shown as percentages or as means ± standard deviation.

2KTR: kidney transplant recipients; HLA: human leukocyte antigen.
At baseline, mean SBP (137.6±25.3 vs. 125.1±13.1 mmHg, p < 0.001) and DBP (85.5±13.9 vs. 80.0±11.0 mmHg, p = 0.002) were higher in NT-PDP (Table 1). There was a trend toward a higher prevalence of both systolic and diastolic hypertension in NT-PDP at baseline, but those differences were not observed throughout the follow-up (Table 3). Percent time within SBP therapeutic goal was similar between groups, whereas DBP was more often within goal in NT-PDP (83.4 vs. 77.3%, RR 0.92, CI 0.88-0.97, p = 0.002).

Baseline median proteinuria (Table 1) and prevalence of significant proteinuria throughout follow-up were similar between groups (Table 3). A trend toward longer periods of untreated significant proteinuria was observed in KTR (17.2 vs. 7.5%, RR 2.27, CI 0.76-6.73, p = 0.137), although KTR were more often within goal (92.7 vs. 83.5%, RR 1.1, CI 1.05-1.16, p < 0.001) (Table 3).

Baseline proteinuria was significantly higher in NT-PDP (13.5±1.5 vs. 12.7±1.6 g/dL, p < 0.001) (Table 1). The prevalence of anemia was higher in KTR at baseline (22.8 vs. 6.9%, OR 3.95, CI 1.61-9.71, p < 0.001) and during follow-up (38.6 vs. 15.8%, RR 2.43, CI 1.46-4.06, p < 0.001); however, the overall percentage of untreated patients was not statistically different between groups. Conversely, the length of time with untreated anemia was much lower for KTR than NT-PDP (11.3 vs. 73.9%, OR 0.15, CI 0.1-0.23, p < 0.001) (Table 3). Both cohorts, however, remained within desired hemoglobin goals for over 92% of the follow-ups, with no difference between them (Table 3).

Baseline HDL tended to be higher in NT-PDP (50.4±14.7 vs. 46.4±13.5 mg/dL, p = 0.056), but total cholesterol and LDL were similar (Table 1). The prevalence of hypercholesterolemia and elevated LDL was similar between groups, both at baseline and during follow-up (Table 3). NT-PDP endured longer periods without treatment of hypercholesterolemia (22.9 vs. 15.7%, OR 0.68, CI 0.32-0.89, p = 0.005), although both cohorts were within specified total cholesterol goals during follow-up (Table 3). LDL values and untreated elevated LDL were not different between groups (Table 3). Conversely, among KTR, hypertriglycerideremia tended to be more common at baseline, was more common throughout follow-up (78.2 vs. 51.0%, OR 1.53, CI 1.23-1.9, p < 0.001), and was less often within goal (58.2 vs. 67.7%, OR 0.85, CI 0.78-0.93, p < 0.001) (Table 3).

Baseline calcium levels were statistically, though not clinically, different between groups (9.4±0.7 in NT-PDP vs. 9.7±0.7 mg/dL in KTR, p = 0.033), and there were no differences in baseline phosphorus, PTH, and 25-OH-vitamin D between groups (Table 1). Prevalence of hyperphosphatemia was similar at baseline and, although time spent with untreated hyperphosphatemia was significantly higher in KTR (56.1 vs. 30.0%, RR 1.86, CI 1.01-3.44, p = 0.044), both cohorts spent approximately 95% of time within goal (Table 3).

Hyperparathyroidism requiring clinical treatment (> 450 pg/mL) was rather uncommon (5.7% in NT-PDP and 4.3% in KTR). No differences in treatment were observed, and both groups remained within PTH goals for over 95% of follow-up (Table 3). Vitamin D deficiency tended to be observed more frequently in NT-PDP at baseline (76.1 vs. 59.2%, OR 0.45, CI 0.18-1.13, p = 0.091), which was not observed during follow-up. Although the time with untreated deficiency was similar between groups, KTR were more often within goal (49.4 vs. 39.2%, RR 1.25, CI 0.96-1.64, p = 0.09) (Table 3).

Baseline uricemia was similar between groups. Although prevalence of hyperuricemia was higher in NT-PDP (30.3 vs. 14.0%, OR 0.37, CI 0.18-0.76, p = 0.006), this difference was not observed during follow-up. KTR had longer untreated hyperuricemia (60.4 vs. 35.4%, RR 1.7, CI 1.31-2.21, p < 0.001), and time within goal was similar between groups (Table 3). Prevalence of metabolic acidosis was similar between groups at baseline and during follow-up. While untreated metabolic acidosis tended to be observed more often in KTR, serum bicarbonate was similarly within range in both groups during follow-up (Table 3).

Kaplan-Meier analysis revealed comparable mortality between the cohorts (3.9% in both cohorts, p = 0.064) (Figure 2). Infections were more common in KTR (50.4 vs. 6.9%, p < 0.001), cardiovascular events were uncommon in both (0.9% in KTR vs. 1.9% in NT-PDP, p = 0.56), as was cancer (5.9% in NT-PDP vs. 2.9% in KTR, p = 0.306). GFR decay was low and not different between groups (0.81 mL/min/year in KTR vs. 1.07 mL/min/year in NT-PDD, p = 0.48, CI 0.04-0.08) (Figure 2). NT-PDP progressed more often to dialysis (9.9% vs. 6.9%, p < 0.001), and the survival for a combined endpoint of death and dialysis tended to be worse among NT-PDP (13.9% vs. 10.9%, p = 0.052) (Figure 2). Patients
**Table 3** CKD-related complications, treatment distribution, and achievement of specific therapeutic goals in NT-PDP and KTR groups throughout follow-up

|                          | NT-PDP (%) | KTR (%) | RR/OR | CI       | p       |
|--------------------------|------------|---------|-------|---------|---------|
| **Hypertension and blood pressure control** |            |         |       |         |         |
| Baseline systolic hypertension | 92.1       | 85.1    | 0.49* | 0.19-1.22 | 0.126   |
| Systolic hypertension in follow-up | 94.1       | 92.1    | 0.97  | 0.9-1.05  | 0.579   |
| Systolic BP within goal | 75.7       | 76.5    | 1.01  | 0.95-1.06 | 0.695   |
| Baseline diastolic hypertension | 92.1       | 86.1    | 0.53* | 0.21-1.33 | 0.18    |
| Diastolic hypertension in follow-up | 94.1       | 93.1    | 0.98  | 0.92-1.06 | 0.774   |
| Diastolic BP within goal | 83.4       | 77.3    | 0.92  | 0.88-0.97 | 0.002   |
| **Proteinuria and anaemia** |            |         |       |         |         |
| Baseline proteinuria > 1g/day | 11.8       | 79      | 0.64* | 0.24-1.67 | 0.36    |
| Proteinuria > 1g/day in follow-up | 22.6       | 23.7    | 1.05  | 0.62-1.75 | 0.845   |
| Patients with untreated proteinuria | 3.2       | 6.9     | 2.14  | 0.57-8.06 | 0.257   |
| Time with untreated proteinuria | 7.5       | 17.2    | 2.27  | 0.76-6.73 | 0.137   |
| Proteinuria within goal | 83.5       | 92.7    | 1.1   | 1.05-1.16 | < 0.001 |
| Baseline anaemia | 6.9       | 22.8    | 3.95* | 1.61-9.71 | 0.002   |
| Anemia in follow-up | 15.8       | 38.6    | 2.43  | 1.46-4.06 | < 0.001 |
| Patients with untreated anemia | 13.8       | 16.8    | 1.21  | 0.63-2.32 | 0.559   |
| Time with untreated anemia | 73.9       | 11.3    | 0.15  | 0.1-0.23  | < 0.001 |
| Hemoglobin within goal | 92.0       | 92.8    | 1.008 | 0.97-1.03 | 0.614   |
| **Lipid abnormalities** |            |         |       |         |         |
| Baseline hypercholesterolemia | 61.4       | 59.4    | 0.92* | 0.52-1.61 | 0.774   |
| Hypercholesterolemia in follow-up | 76.2       | 78.2    | 1.02  | 0.88-1.19 | 0.737   |
| Patients with untreated Hypercholesterolemia | 40.6       | 38.6    | 0.95  | 0.67-1.33 | 0.773   |
| Time with untreated hypercholesterolemia | 22.9       | 15.7    | 0.68  | 0.52-0.89 | 0.005   |
| Total cholesterol within goal | 66.4       | 69.9    | 1.05  | 0.97-1.13 | 0.188   |
| Baseline elevated LDL cholesterol | 82.0       | 76.2    | 0.7*  | 0.36-1.39 | 0.316   |
| Elevated LDL cholesterol in follow-up | 92.0       | 88.1    | 0.95  | 0.87-1.05 | 0.358   |
| Patients with untreated elevated LDL | 60.6       | 51.5    | 0.83  | 0.65-1.06 | 0.15    |
| Time with untreated elevated LDL | 35.6       | 31.0    | 0.87  | 0.73-1.03 | 0.117   |
| LDL cholesterol within goal | 40.3       | 45.7    | 1.13  | 0.98-1.3  | 0.07    |
| Baseline hypertriglyceridemia | 28.0       | 37.6    | 1.55* | 0.85-2.8  | 0.147   |
| Hypertriglyceridemia in follow-up | 51.0       | 78.2    | 1.53  | 1.23-1.9  | < 0.001 |
| Triglyceridemia within goal | 67.7       | 58.2    | 0.85  | 0.78-0.93 | < 0.001 |
| **Bone mineral disorder** |            |         |       |         |         |
| Baseline hyperphosphatemia | 5.5        | 4.9     | 0.89* | 0.25-3.2  | 0.865   |
| Hyperphosphatemia in follow-up | 12.7       | 19.8    | 1.55  | 0.8-2.99  | 0.191   |
| Patients w/ untreated hyperphosphatemia | 7.4        | 18.8    | 2.52  | 1.11-5.73 | 0.026   |
| Time with untreated hyperphosphatemia | 30.0       | 56.1    | 1.86  | 1.01-3.44 | 0.044   |
| Phosphataemia within goal | 94.9       | 95.5    | 1.006 | 0.97-1.03 | 0.654   |
| Baseline hyperparathyroidism | 1.4        | 2.9     | 2.05* | 0.18-23.2 | 0.559   |
| Hyperparathyroidism in follow-up | 5.7        | 4.3     | 0.76  | 0.17-3.27 | 0.713   |
| Patients with untreated hyperparathyroidism | 2.8        | 4.4     | 1.52  | 0.26-8.82 | 0.639   |
Table 3. Continued.

| Time with untreated hyperparathyroidism | 30.0 | 25.0 | 0.83 | 0.24-2.8 | 0.768 |
| PTH within goal | 95.3 | 95.7 | 1.003 | 0.95-1.05 | 0.873 |
| Baseline hypovitaminosis D | 76.1 | 59.2 | 0.45* | 0.18-1.13 | 0.091 |
| Hypovitaminosis D in follow-up | 84.1 | 77.8 | 0.92 | 0.74-1.15 | 0.489 |
| Patients with untreated hypovitamin D | 53.4 | 66.6 | 1.24 | 0.89-1.73 | 0.188 |
| Time with untreated hypovitamin D | 28.3 | 33.3 | 1.17 | 0.82-1.68 | 0.368 |
| 25-OH Vitamin D within goal | 39.2 | 49.4 | 1.25 | 0.96-1.64 | 0.09 |

Other metabolic parameters

| Baseline hyperuricemia | 30.3 | 14.0 | 0.37* | 0.18-0.76 | 0.006 |
| Hyperuricemia in follow-up | 40.4 | 39.0 | 0.96 | 0.68-1.35 | 0.839 |
| Patients with untreated hyperuricemia | 28.3 | 34.0 | 1.02 | 0.79-1.82 | 0.385 |
| Time with untreated hyperuricemia | 35.4 | 60.4 | 1.7 | 1.31-2.21 | < 0.001 |
| Uricemia within goal | 83.9 | 87.2 | 1.03 | 0.98-1.09 | 0.146 |
| Baseline metabolic acidosis | 17.5 | 19.4 | 1.13* | 0.46-2.78 | 0.783 |
| Metabolic acidosis in follow-up | 28.1 | 34.7 | 1.23 | 0.73-2.08 | 0.425 |
| Patients with untreated metabolic acidosis | 3.5 | 12.5 | 3.56 | 0.8-15.84 | 0.095 |
| Time with untreated metabolic acidosis | 2.6 | 8.5 | 3.3 | 0.74-14.7 | 0.116 |
| Serum bicarbonate within goal | 86.4 | 90.1 | 1.04 | 0.96-1.13 | 0.316 |

Data are shown as percentages. Frequencies were compared using Chi-square or Fisher’s test.

1Data are shown as percentages. Frequencies were compared using Chi-square or Fisher’s test.

2NT-PDP: non-transplanted pre-dialysis patients; KTR: kidney transplant recipients; OR: odds ratio; RR: relative risk; CI: confidence interval; BP: blood pressure. LDL: low-density lipoprotein; HDL: high-density lipoprotein. *OR (odds ratio).

from both cohorts who progressed to dialysis were younger, with lower baseline GFR, and more often had glomerulonephritis as the primary cause of CKD (Table 4).

DISCUSSION

Multidisciplinary teamwork provides better long-term results for patients with chronic conditions such as CKD. KTR are a particular subset of patients in which CKD-related complications and risk factors for disease progression concur with major immunological concerns and the use of immunosuppression drugs. The importance of multidisciplinary approach in KTR has been suggested by studies comparing multidisciplinary and non-multidisciplinary post-transplant clinics. In our retrospective study, we compared KTR and NT-PDP groups after PSM, both under multidisciplinary follow-up. The cohorts had similar eGFR, CKD category distribution, and prevalence of diabetes and cardiovascular comorbidities, but KTR were younger and had longer follow-up. Time within most therapeutic goals was similar between groups, with the exception of DBP and triglyceridemia, controlled for longer in NT-PDP, and proteinuria, controlled for longer in KTR. Patient survival and GFR decay were similar between groups, although NT-PDP progressed earlier to dialysis.

Anemia was more common and treated more often in KTR, partly because most anemic KTR were already using erythropoietin at the study onset, whereas most NT-PDP were incident patients. The similar absolute percentage of patients from each cohort with untreated anemia at any point in time (13.8% vs. 16.8%, p = 0.559) reinforces that observation. Akbari et al., in a transversal study, described worse results, with 59% of KTR without multidisciplinary care, and 21% of NT-PDP with multidisciplinary care, to be with untreated anemia. The finding of proteinuria in KTR being more often controlled should be considered with caution, since proteinuria in NT-PDP usually has a different meaning than in KTR. Especially after 1 year post-transplant, proteinuria could represent a number of concurrent conditions implied in tubulo-interstitial derangement.
of the graft, in the context of multifactorial chronic allograft nephropathy, such as alloimmune response, recurrent or de novo glomerulonephritis, or adverse effects of immunosuppressive medications, notably mammalian target of rapamycin inhibitors (m-TORi).\(^{19,20}\)

Interestingly, we observed a downslope of eGFR in the first year of follow-up in NT-PDP, followed by a less steep curve, probably reflecting the introduction and dose adjustments of antihypertensive medications, particularly angiotensin-converting enzyme inhibitors (ACEi) or angiotensin receptor blockers (ARB), in incident patients entering the NT-PDP cohort. This observation is paralleled by mean SBP and DBP being higher in PDP at baseline, which was not persistent throughout follow-up. Overall, both cohorts had SBP and DBP controlled for over 75% of the observation period. Due to the variable nature of available studies, straight comparisons cannot be drawn between their results and ours. Carpenter et al. described controlled BP (< 130/80 mmHg) in 56% of KTR, whereas Bissonnette et al. found 65% of SBP and 88% of DBP to be controlled in KTR with GFR < 30 mL/min/m\(^2\) under multidisciplinary care. Akbari et al. reported 40% of KTR in category 5 of CKD had controlled BP without multidisciplinary care.\(^{13,14,21}\)

The higher prevalence and poorer control of hypertriglyceridemia in KTR were probably related to side effects of immunosuppressive drugs, such as prednisone, calcineurin inhibitors, and mammalian-target of rapamycin inhibitors (m-TORi).\(^{22}\) Although untreated hypercholesterolemia was less often

---

**Figure 2.** Glomerular filtration rate variation with discrete (A) and continuous time (B), and Kaplan-Meier curves for death (C), dialysis (D), and death or dialysis (E). eGFR: estimated glomerular filtration rate; NT-PDP: non-transplanted pre-dialysis patients; KTR: kidney transplant recipient.
observed in KTR, concerns regarding avoidance of polypharmacy, potentially harmful drug interactions, and adverse drug effects may have prevented the use of fibrates in KTR. Similar findings were reported by Akbari et al., who described hypertriglyceridemia in 67% of KTR without multidisciplinary treatment and in 50% of NT-PDP under multidisciplinary care. In the present study, we observed hypertriglyceridemia in 67.7% of KTR and 58.2% of NT-PDP, despite multidisciplinary follow-up in both cohorts.\(^\text{13}\)

Polypharmacy avoidance could also partly explain why KTR had untreated hyperphosphatemia and hyperuricemia for longer periods. However, no differences were observed in the percentage of clinical visits wherein both phosphate and uric acid were within goals for both cohorts. Again, as a comparison, Akbari et al. described untreated hyperphosphatemia in 71.4% of category 5 KTR in a non-multidisciplinary setting, and in 13.3% of category 5 NT-PDP under multidisciplinary care.\(^\text{13}\) Bissonnette et al., later described the use of phosphate chelators in 73% KTR under multidisciplinary treatment, as opposed to 25% KTR in non-multidisciplinary setting, despite the ease of attaining clinical targets for hyperphosphatemia in both cohorts (90% and 85%, respectively, without statistical difference).\(^\text{14}\)

Patient survival was similar between groups. The observed GFR decline was very slow and similar in both cohorts, although NT-PDP progressed to dialysis earlier.\(^\text{3,23}\) Considering the nature of the KTR we studied, who mostly received living, related-donor grafts, and whose characteristics led to the NT-PDP cohort selected through PSM, the results we described must be carefully compared to those from other authors.\(^\text{7,13}\) Still, we demonstrated that throughout follow-up, the percentage of time within most therapeutic goals was similar between groups, indicating a positive result based on the hypothesis that multidisciplinary care could provide high quality treatment for CKD in KTR, similarly to NT-PDP, as previously suggested.\(^\text{13,18}\)

Some important limitations of this study include its single-center, retrospective non-randomized study design, and its relatively small sample of KTR.

### Table 4: Demographic Characteristics and Progression to Dialysis

|                        | NT-PDP progressed to dialysis (N = 10) | NT-PDP not progressed to dialysis (N = 91) | KTR progressed to dialysis (N = 7) | KTR not progressed to dialysis (N = 94) |
|------------------------|----------------------------------------|-------------------------------------------|-----------------------------------|----------------------------------------|
| **Primary cause of CKD** |                                        |                                           |                                   |                                        |
| Glomerulonephritis     | 60.0                                   | 7.7                                       | 57.1                              | 39.3                                   |
| Hypertension           | 20.0                                   | 46.1                                      | 0.0                               | 22.3                                   |
| Diabetes               | 10.0                                   | 3.3                                       | 14.3                              | 1.1                                    |
| Polycystic kidney disease | 0.0                                   | 13.2                                      | 0.0                               | 5.3                                    |
| Other                  | 10.0                                   | 6.6                                       | 14.3                              | 5.3                                    |
| Undetermined           | 0.0                                    | 23.1                                      | 14.3                              | 26.6                                   |
| **Baseline renal function** |                                      |                                           |                                   |                                        |
| Creatinine (mg/dL)     | 2.58 ± 0.89                            | 1.51 ± 0.47                               | 2.24 ± 1.00                       | 1.54 ± 0.45                            |
| eGFR (mL/min/1.73m²)   | 33.4 ± 12.4                            | 53.7 ± 19.9                               | 37.23 ± 13.0                      | 54.4 ± 16.6                            |
| **Demographics**       |                                        |                                           |                                   |                                        |
| Female gender (%)      | 30.0                                   | 38.5                                      | 57.1                              | 29.8                                   |
| Age (years)            | 36.6 ± 11.0                            | 51.8 ± 12.9                               | 36.3 ± 11.8                       | 43.9 ± 12.5                            |
| **Donor type (%)**     |                                        |                                           |                                   |                                        |
| Living related         | -                                      | -                                         | 85.7                              | 85.1                                   |
| Living unrelated       | -                                      | -                                         | 14.3                              | 11.7                                   |
| Deceased               | -                                      | -                                         | 0.0                               | 3.2                                    |

\(^1\text{Data are shown as percentages or means ± standard deviation.}\)

\(^2\text{NT-PDP: non-transplanted pre-dialysis patients. KTR: kidney transplant recipients.}\)

\(^3\text{eGFR: estimated glomerular filtration rate, according to the CKD-EPI formula.}\)

CKD: chronic kidney disease.
compared to mostly incident NT-PDP. This may account for the protection against hard endpoints in the KTR group and also limits the inference about CKD progression. To correct the demographic disparities, we employed “nearest neighbor” PSM, obtaining the best possible sample of NT-PDP from a larger cohort to match the KTR. Despite not being able to fully match the cohorts for age, BMI, and length of follow-up, we were able to equalize both cohorts in terms of GFR and CKD stage, the prevalence of diabetes, and cardiovascular comorbidities. Considering there is no strong evidence supporting the beneficial effect of CKD management in KTR, we chose to adopt, as KDIGO 2012 suggests, the current CKD treatment recommendations for the KTR and NT-PDP. Few well-designed studies have described the beneficial impact of multidisciplinary care on KTR, and only one cross-sectional study has demonstrated comparable quality of multidisciplinary treatment of CKD-related complications between NT-PDP and KTR. The present study is the first to compare the quality of treatment of CKD-related complications throughout a specified follow-up period, between KTR and NT-PDP cohorts, when both were under multidisciplinary care. Besides, this is one of the few studies about CKD treatment in a Brazilian KTR population.

In conclusion, the percentage of time spent within most therapeutic goals was similar between the cohorts. Despite being based on a small sample, we found comparable patient survival, and GFR decline, although NT-PDP more often progressed to dialysis. The observed results suggest that multidisciplinary clinics could contribute for good quality follow-up of KTR.

ABBREVIATIONS

ACEi, angiotensin-converting enzyme inhibitors
ARB, angiotensin receptor blockers
ASA, acetylsalicylic acid
BMI, body mass index
BP, blood pressure
CI, confidence interval
CKD, chronic kidney disease
CKD-EPI, Chronic Kidney Disease Epidemiology Collaboration
DBP, diastolic blood pressure
eGFR, estimated glomerular filtration rate
GFR, glomerular filtration rate
HDL, high-density lipoprotein
HLA, human leukocyte antigen
KDIGO, Kidney Disease Improving Global Outcomes
KTR, kidney transplant recipients
LDL, low-density lipoprotein
m-TORi, mammalian-target of rapamycin inhibitor
NT-PDP, non-transplanted pre-dialysis patients
PDP, pre-dialysis patients
PSM, propensity score-matching
PTH, parathyroid hormone
RR, relative risk
RRT, renal replacement therapy
SBP, systolic blood pressure

ACKNOWLEDGEMENTS

We thank Bárbara Bruna Abreu de Castro for assistance with graphic editing.

AUTHOR’S CONTRIBUTION

Every author took part in study design, data collection, analysis and interpretation, article writing and editing, as well as final approval of the manuscript.

CONFLICT OF INTEREST

The authors declare no conflicts of interest.

REFERENCES

1. Wolfe RA, Ashby VB, Milford EL, Ojo AO, Ettenger RE, Agodoa LY, et al. Comparison of mortality in all patients on dialysis, patients on dialysis awaiting transplantation, and recipients of a first cadaveric transplant. N Engl J Med. 1999 Dec;341(23):1725-30.
2. Djamali A, Samaniego M, Muth B, Muehrer R, Hofmann RM, Pirsch J, et al. Medical care of kidney transplant recipients after the first posttransplant year. Clin J Am Soc Nephrol. 2006 Jul;1(4):623-40.
3. Djamali A, Kendzierski C, Brazy PC, Becker BN. Disease progression and outcomes in chronic kidney disease and renal transplantation. Kidney Int. 2003 Nov;64(5):1800-7.
4. Pesavento TE. Kidney transplantation in the context of renal replacement therapy. Clin J Am Soc Nephrol. 2009 Dec;4(12):2035-9.
5. Kidney Disease: Improving Global Outcomes (KDIGO). KDIGO 2012 Clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int (Suppl). 2013;3(1):S1-150.
6. Meier-Kriesche HU, Schold JD, Srinivas TR, Kaplan B. Lack of improvement in renal allograft survival despite a marked decrease in acute rejection rates over the most recent era. Am J Transplant. 2004 Mar;4(3):378-83.
7. Gondos A, Döhler B, Brenner H, Opezzo G. Kidney graft survival in Europe and the United States: strikingly different long-term outcomes. Transplantation. 2013 Jan;95(2):267-74.
8. Nankivell BJ, Kuypers DRJ. Diagnosis and prevention of chronic kidney allograft loss. Lancet. 2011 Oct;378(9800):1428-37.
9. Lamb KE, Lodhi S, Meier-Kriesche HU. Long-term renal allograft survival in the United States: a critical reappraisal. Am J Transplant. 2011 Mar;11(3):450-62.
10. Legendre C, Canaud G, Martinez F. Factors influencing long-term outcome after kidney transplantation. Transplant Int. 2014 Jan;27(1):19-27.
11. Thanamayooran S, Rose C, Hirsch DJ. Effectiveness of a multidisciplinary kidney disease clinic in achieving treatment guideline targets. Nephrol Dial Transplant. 2005;20(11):2385-93.
12. Hemmelgarn BR, Manns BJ, Zhang J, Tonelli M, Klarenbach S, Walsh M, et al. Association between multidisciplinary care and survival for elderly patients with chronic kidney disease. J Am Soc Nephrol. 2007 Mar;18(3):993-9.
13. Akbari A, Hussain N, Karpinski J, Knoll GA. Chronic kidney disease management: comparison between renal transplant recipients and nontransplant patients with chronic kidney disease. Nephron Clin Pract. 2007;107(1):c7-13.
14. Bissonnette J, Woodend K, Davies B, Stacey D, Knoll GA. Evaluation of a collaborative chronic care approach to improve outcomes in kidney transplant recipients. Clin Transplant. 2013 Mar/Apr;27(2):232-8.
15. Sociedade Brasileira de Nefrologia (SBN). Diretrizes brasileiras de doença renal crônica. Braz J Nephrol [Internet]. 2004; [cited 2016 May 17]; 26(3 Suppl 1):S1-49. Available from: http://www.nefrologiaonline.com.br/Diretrizes/irc.htm
16. Rubin DB. Estimating causal effects from large data sets using propensity scores. Ann Intern Med. 1997 Oct;127(8 Pt 2):757-63.
17. Levey AS, Stevens LA, Schmid CH, Zhang YL, Castro AF, Feldman HI, et al. A new equation to estimate glomerular filtration rate. Ann Intern Med. 2009 May;150(9):604-12.
18. Curtis BM, Ravani P, Malberti F, Kennett F, Taylor PA, Djurdjev O, et al. The short- and long-term impact of multi-disciplinary clinics in addition to standard nephrology care on patient outcomes. Nephrol Dial Transplant. 2005 Jan;20(1):147-54.
19. Ponticelli C, Graziani G. Proteinuria after kidney transplantation. Transplant Int. 2012 Sep;25(9):909-17.
20. Halimi JM. Low-grade proteinuria and microalbuminuria in renal transplantation. Transplantation. 2013 Jul;96(2):121-30.
21. Carpenter MA, Weir MR, Adey DB, House AA, Bostom AG, Kusek JW. Inadequacy of cardiovascular risk factor management in chronic kidney transplantation – evidence from the FAVORIT study. Clin Transplant. 2012 Jul/Aug;26(4):E438-46.
22. Halloran P. Immunosuppressive drugs for kidney transplantation. N Engl J Med. 2004 Dec;351(26):2715-29.
23. Kuakla A, Adulla M, Pascual J, Samaniego M, Nancovic I, Becker BN, et al. CKD stage-to-stage progression in native and transplant kidney disease. Nephrol Dial Transplant. 2007 Feb;23(2):693-700.
24. Carminatti M, Fernandes NMS, Colugnati FAB, Sanderson-Pinheiro H. Are kidney transplant patients receiving chronic kidney disease treatment? A comparative study to predialysis patients in a multidisciplinary setting. Exp Clin Transplant. 2016 Oct;14(5):491-6.